Study: Potential biomarkers of AAV-associated kidney disease identified

Long-term Nucala or benralizumab effective in EGPA real-world study

Two years of treatment with Nucala (mepolizumab) safely and effectively reduces signs and symptoms of hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis. That’s according to a real-world study in Italy that also found similar outcomes with benralizumab, a therapy that works similarly to…

Antibody-targeted approach bests plasma exchange in AAV: Study

An approach that removes specific antibodies from a person’s blood is better than a standard, more general blood-cleaning procedure called plasma exchange at clearing the self-reactive antibodies that drive ANCA-associated vasculitis (AAV). That’s according to a small study in China that looked at data from AAV patients with severe…

Healthy pregnancy possible, especially if disease in remission

Rates of preterm delivery, lower-than-normal birth weight, and maternal disease flares are higher among pregnant women with ANCA-associated vasculitis (AAV) than in the general population, according to a review study. Despite this, “most pregnancies resulted in healthy newborns and manageable, non-life-threatening flares of AAV,” the researchers wrote, suggesting that “pregnancy…